กระทรวงสาธารณสุขของประเทศไทยและองค์การอนามัยโลก ได้จัดทำยุทธศาสตร์ความร่วมมือระหว่างรัฐบาลไทยและองค์การอนามัยโลก (WHO Country Co

COVID-19 disease models have aided policymakers in low-and middle-income countries (LMICs) with many critical decisions. Many challenges remain surrounding their use, from inappropriate model selection and adoption, inadequate and untimely reporting of evidence, to the lack of iterative stakeholder

Abstract Background There is very limited evidence examining serious systemic adverse events (SSAEs) and post-injection endophthalmitis of intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) treatments in Thailand and low- and middle-income countries. Moreover, findings from the ex

Why do we need to make health technology assessment (HTA) more realistic? Is HTA not realistic nowadays? The answers can be both YES and NO.HTA is a form of research for synthesising data to evaluate properties, effects, and impacts of health interventions and technology in diffe

This short training aims to equip administrator and medical instructors with skill in the selection of appropriate health technologies, and to give guidance in doing a relevant research that benefit the country.  201-203-2553Capacity building,Consortium of Thai Medical Schools,ความร่วมมือ

Because of their rarity, rare diseases are often treated with what the industry refers to as ‘orphan drugs’. These group of drugs are quite expensive because of the fewer number of people suffering from such sickness and usually provide low profit to manufacturer compared to other common drug for n

Management of advanced prostate cancer, particularly in cases of metastatic castration-resistant prostate cancer (mCRPC), typically involves first-line treatment with the chemotherapeutic agent docetaxel. Nevertheless, disease progression following docetaxel therapy remains a major challenge, as there are currently no therapeutic options listed in